NCT03648905View on ClinicalTrials.gov

Clinical Laboratory Evaluation of Chronic Autonomic Failure

Active, not recruitingOBSERVATIONAL
Enrollment

89

Participants

Timeline

Start Date

September 6, 2018

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2029

Conditions
Parkinson's DiseaseMultiple System AtrophyAutonomic Failure
Interventions
DRUG

13N-Ammonia

a perfusion imaging agent

DRUG

18F-DOPA

is a positron-emitting analog of the catechol amino acid, levodopa

DRUG

11C-Methylreboxetine (11C-MRB)

11C-MRB may be injected IV for visualizingsites of neuronal uptake of norepinephrine in the brain or periphery by PET scanning. Setup includes placement of an arm IV catheter. 11C-MRB is a Radioactive Research Drug.

DRUG

18F-Dopamine

is a positron-emitting analog of the catecholamine, dopamine

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

NCT03648905 - Clinical Laboratory Evaluation of Chronic Autonomic Failure | Biotech Hunter | Biotech Hunter